A STUDY TO ASSESS PHARMACOKINETICS AND SAFETY OF ATEZOLIZUMAB ADMINISTERED INTRAVENOUSLY (IV) AS A SINGLE AGENT OR IN COMBINATION WITH CHEMOTHERAPY TO CHINESE PARTICIPANTS WITH LOCALLY ADVANCED OR METASTATIC SOLID TUMORS: